吉非替尼联合培美曲塞治疗晚期非小细胞肺癌疗效临床评价

Clinical Evaluation of Gefitinib Combined with Pemetrexed in the Treatment of Advanced Non-Small Cell Lung Cancer

目的探讨吉非替尼联合培美曲塞治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法选取安徽省亳州市人民医院2019年8月至2020年8月收治的晚期NSCLC患者180例,按随机数字表法分为对照组和观察组,各90例。两组患者均静脉滴注培美曲塞,观察组患者加用吉非替尼。两组均连续给药9周。结果观察组患者的客观缓解率为36.67%,显著高于对照组的22.22%(P<0.05);治疗后,观察组患者的血清肿瘤标志物犤细胞角蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)犦水平均显著低于对照组(P<0.05);观察组患者的卡氏(KPS)评分显著高于对照组,视觉模拟评分法(VAS)评分显著低于对照组(P<0.05);两组患者的不良反应发生率无显著差异(P>0.05)。结论吉非替尼联合培美曲塞治疗晚期NSCLC疗效较好,能延缓疾病进展,降低肿瘤标志物水平,改善患者的生活质量,且安全性较高。

Objective To investigate the clinical efficacy and safety of gefitinib combined with pemetrexed in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 180 patients with advanced NSCLC admitted to the Bozhou People’s Hospital from August 2019 to August 2020 were selected and divided into the control group and the observation group according to the random number table method,90 cases in each group.The patients in the two groups were treated with pemetrexed by intravenous drip,while the patients in the observation group were treated with gefitinib.Both groups were continuously treated for nine weeks as a cycle.Results The objective remission rate of the observation group was 36.67%,which was significantly higher than 22.22% of the control group(P<0.05).After treatment,the levels of serum tumor markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the Karnofsky score in the observation group was significantly higher than that in the control group,while the visual analogue scale(VAS)score in the observation group was significantly higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Gefitinib combined with pemetrexed is effective and safe in the treatment of advanced NSCLC,which can delay the disease progression,reduce the level of tumor markers,and improve the quality of life of patients.